Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

: Aging is a well-established independent risk factor for both cognitive impairment and sleep disorders, including obstructive sleep apnea (OSA), a modifiable yet underrecognized condition. OSA has been implicated in biological mechanisms contributing to Alzheimer's disease, including amyloid-β accumulation, tau phosphorylation, and neuroinflammation. This underscores the need to optimize OSA diagnosis in individuals with an increased risk of dementia. : This cross-sectional observational study enrolled adults aged 60-85 years with a CAIDE dementia risk score ≥6. Subjective sleep was evaluated using validated questionnaires (Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and the Oviedo Sleep Questionnaire), while objective sleep data were obtained through a single-night peripheral arterial tonometry (PAT)-based wearable device, complemented by a 7-day sleep diary. Participants also completed the STOP-BANG and Berlin questionnaires, with clinically relevant findings communicated to participants. : Among 322 participants (48.8% women; mean age 71.4 ± 6.4 years), moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥ 15) was identified in 48.49%, despite the absence of prior diagnoses. Subjective screening tools frequently underestimated OSA severity compared to objective assessments. While no significant sex-based differences were noted, higher AHI values correlated strongly with increased body mass index and elevated dementia risk scores. : A marked discrepancy between subjective and objective sleep measurements complicates the accurate diagnosis and management of most sleep disorders, including OSA. Sleep disorders remain significantly underdiagnosed in individuals at increased risk for dementia. Integrating wearable technologies and structured tools such as sleep diaries into routine assessments can enhance diagnostic precision, enabling timely interventions for these modifiable risk factors of dementia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12027575PMC
http://dx.doi.org/10.3390/jcm14082607DOI Listing

Publication Analysis

Top Keywords

sleep
12
increased risk
12
risk dementia
12
sleep disorders
12
sleep apnea
8
disorders including
8
individuals increased
8
dementia risk
8
objective sleep
8
risk
7

Similar Publications

Obstructive sleep apnea-hypopnea syndrome (OSAHS) is an underrated and heavy public health problem. Polysomnography (PSG) remains GOLD-standard examination but we also use ambulatory screening tests including Brizzy, which measures mandibular movements. The aim is to report on our experience with the Brizzy and compare it with PSG data.

View Article and Find Full Text PDF

This study aimed to estimate the occurrence of excessive daytime sleepiness (EDS) and its associated factors among male road transport workers. A cross-sectional study was conducted with a non-probabilistic sample of 414 drivers recruited at gas stations and parking lots in Formosa and Rio Verde, Goiás, Brazil, in 2024. The presence of EDS was evaluated using the Epworth Sleepiness Scale, and the investigated associated factors included demographic, socioeconomic, behavioural, health and professional characteristics.

View Article and Find Full Text PDF

Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial.

J Dermatolog Treat

December 2025

Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.

Background: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).

Objectives: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.

Methods: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed.

View Article and Find Full Text PDF

Slowing down the clock on ovarian aging-does the ovary hold the secret to the fountain of youth?

Geroscience

September 2025

NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

In the past century, the human Lifespan has doubled. However, this is not equivalent to Healthspan which refers to the number of years spent healthy and free from disease. Women have an additional level of complexity on the path to optimal healthspan where health resilience dramatically decreases following menopause and this is due to their ovaries aging by midlife.

View Article and Find Full Text PDF